> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# HHS Inspector General Assessing Device Surveillance
- URL: https://www.fdaweb.com/hhs-inspector-general-assessing-device-surveillance/
- Published: 2019-10-16T12:00:00.000Z
- Updated: 2026-09-15T01:56:58.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5145265

HHS’s Office of Inspector General (OIG)says it is assessing FDA’s medical device postmarket surveillance activities. “As the information that the FDA receives about medical device safety and effectiveness is increasingly gathered in the postmarket setting, it is more important than ever that FDA’s postmarket safety surveillance system can effectively identify and act on safety signals,” OIG says in an [work plan update](https://oig.hhs.gov/reports-and-publications/workplan/summary/wp-summary-0000406.asp?ref=fdaweb.com).  

OIG says it will complete and report on its assessment in 2020\. “We will assess and describe how FDA’s established passive postmarket surveillance system identifies and tracks safety concerns, and assess FDA’s response to those concerns,” it says. “We will also describe how elements of FDA’s newer surveillance system initiatives, such as the Unique Device Identification system, are being integrated into the passive postmarket surveillance system. In addition, we will describe how FDA plans to integrate these initiatives into the National Evaluation System for health Technology, its in-development active postmarket surveillance system.”